Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a/2b Study of Vatelizumab in Relapsing-Remitting Multiple Sclerosis
2014-001643-20Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Vatelizumab with Placebo (2 arms). Primary endpoint: Cumulative number of new contrast-enhancing lesions on MRI. Started Aug 2014; status: terminated.
02
Drugs
vatelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2014-001643-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001643-20.